Skip to main content
Top
Published in: BMC Infectious Diseases 1/2022

Open Access 01-12-2022 | Human Immunodeficiency Virus | Study protocol

Studying patterns and predictors of HIV viral suppression using A Big Data approach: a research protocol

Authors: Jiajia Zhang, Bankole Olatosi, Xueying Yang, Sharon Weissman, Zhenlong Li, Jianjun Hu, Xiaoming Li

Published in: BMC Infectious Diseases | Issue 1/2022

Login to get access

Abstract

Background

Given the importance of viral suppression in ending the HIV epidemic in the US and elsewhere, an optimal predictive model of viral status can help clinicians identify those at risk of poor viral control and inform clinical improvements in HIV treatment and care. With an increasing availability of electronic health record (EHR) data and social environmental information, there is a unique opportunity to improve our understanding of the dynamic pattern of viral suppression. Using a statewide cohort of people living with HIV (PLWH) in South Carolina (SC), the overall goal of the proposed research is to examine the dynamic patterns of viral suppression, develop optimal predictive models of various viral suppression indicators, and translate the models to a beta version of service-ready tools for clinical decision support.

Methods

The PLWH cohort will be identified through the SC Enhanced HIV/AIDS Reporting System (eHARS). The SC Office of Revenue and Fiscal Affairs (RFA) will extract longitudinal EHR clinical data of all PLWH in SC from multiple health systems, obtain data from other state agencies, and link the patient-level data with county-level data from multiple publicly available data sources. Using the deidentified data, the proposed study will consist of three operational phases: Phase 1: “Pattern Analysis” to identify the longitudinal dynamics of viral suppression using multiple viral load indicators; Phase 2: “Model Development” to determine the critical predictors of multiple viral load indicators through artificial intelligence (AI)-based modeling accounting for multilevel factors; and Phase 3: “Translational Research” to develop a multifactorial clinical decision system based on a risk prediction model to assist with the identification of the risk of viral failure or viral rebound when patients present at clinical visits.

Discussion

With both extensive data integration and data analytics, the proposed research will: (1) improve the understanding of the complex inter-related effects of longitudinal trajectories of HIV viral suppressions and HIV treatment history while taking into consideration multilevel factors; and (2) develop empirical public health approaches to achieve ending the HIV epidemic through translating the risk prediction model to a multifactorial decision system that enables the feasibility of AI-assisted clinical decisions.
Literature
1.
go back to reference Harris NS, Johnson AS, Huang Y-LA, Kern D, Fulton P, Smith DK, et al. Vital signs: Status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. MMWR Morb Mort Wkly Rep. 2019;68(48):1117–23.CrossRef Harris NS, Johnson AS, Huang Y-LA, Kern D, Fulton P, Smith DK, et al. Vital signs: Status of human immunodeficiency virus testing, viral suppression, and HIV preexposure prophylaxis—United States, 2013–2018. MMWR Morb Mort Wkly Rep. 2019;68(48):1117–23.CrossRef
2.
go back to reference Lee JS, Cole SR, Richardson DB, Dittmer DP, Miller WC, Moore RD, et al. Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. AIDS. 2017;31(14):1989–97.CrossRef Lee JS, Cole SR, Richardson DB, Dittmer DP, Miller WC, Moore RD, et al. Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation. AIDS. 2017;31(14):1989–97.CrossRef
6.
go back to reference Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460–5.CrossRef Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4):460–5.CrossRef
7.
go back to reference Palmer A, Gabler K, Rachlis B, Ding E, Chia J, Bacani N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine (Baltimore). 2018;97(22):e10562.CrossRef Palmer A, Gabler K, Rachlis B, Ding E, Chia J, Bacani N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine (Baltimore). 2018;97(22):e10562.CrossRef
8.
go back to reference Kakkar F, Lee T, Hawkes MT, Brophy J, Lindy S, Singer J, et al. Challenges to achieving and maintaining viral suppression among children living with HIV. AIDS. 2020;34(5):687–97.CrossRef Kakkar F, Lee T, Hawkes MT, Brophy J, Lindy S, Singer J, et al. Challenges to achieving and maintaining viral suppression among children living with HIV. AIDS. 2020;34(5):687–97.CrossRef
9.
go back to reference Hermans LE, Moorhouse M, Carmona S, Grobbee DE, Hofstra LM, Richman DD, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18(2):188–97.CrossRef Hermans LE, Moorhouse M, Carmona S, Grobbee DE, Hofstra LM, Richman DD, et al. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study. Lancet Infect Dis. 2018;18(2):188–97.CrossRef
10.
go back to reference Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol. 2007;45(10):3436–8.CrossRef Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol. 2007;45(10):3436–8.CrossRef
11.
go back to reference Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis. 2009;48(2):260–2.CrossRef Gatanaga H, Tsukada K, Honda H, Tanuma J, Yazaki H, Watanabe T, et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clin Infect Dis. 2009;48(2):260–2.CrossRef
12.
go back to reference Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, et al. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr. 2010;54(4):442–4.CrossRef Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, et al. Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test. J Acquir Immune Defic Syndr. 2010;54(4):442–4.CrossRef
13.
go back to reference Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54(5):724–32.CrossRef Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2012;54(5):724–32.CrossRef
14.
go back to reference Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis. 2012;25(1):17–25.CrossRef Doyle T, Geretti AM. Low-level viraemia on HAART: significance and management. Curr Opin Infect Dis. 2012;25(1):17–25.CrossRef
15.
go back to reference Gianotti N, Galli L, Salpietro S, Cernuschi M, Bossolasco S, Maillard M, et al. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clin Microbiol Infect. 2013;19(12):E542–4.CrossRef Gianotti N, Galli L, Salpietro S, Cernuschi M, Bossolasco S, Maillard M, et al. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clin Microbiol Infect. 2013;19(12):E542–4.CrossRef
16.
go back to reference Navarro J, Caballero E, Curran A, Burgos J, Ocana I, Falco V, et al. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment. Antivir Ther. 2016;21(4):345–52.CrossRef Navarro J, Caballero E, Curran A, Burgos J, Ocana I, Falco V, et al. Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment. Antivir Ther. 2016;21(4):345–52.CrossRef
17.
go back to reference Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58(7):3585–98.CrossRef Ryscavage P, Kelly S, Li JZ, Harrigan PR, Taiwo B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob Agents Chemother. 2014;58(7):3585–98.CrossRef
19.
go back to reference Tanner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis. 2016;16(1):590.CrossRef Tanner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A, et al. Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis. 2016;16(1):590.CrossRef
20.
go back to reference Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D, et al. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis. 2003;37(11):1517–26.CrossRef Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D, et al. Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy. Clin Infect Dis. 2003;37(11):1517–26.CrossRef
21.
go back to reference Pellegrino R, Griffith D, Agwu A. patterns of retention in HIV care and factors associated with viral suppression in youth and young adults age 18–30 with HIV in an urban practice. J Adolesc Health. 2019;64(2):S97.CrossRef Pellegrino R, Griffith D, Agwu A. patterns of retention in HIV care and factors associated with viral suppression in youth and young adults age 18–30 with HIV in an urban practice. J Adolesc Health. 2019;64(2):S97.CrossRef
22.
go back to reference Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69(12):2145–52.CrossRef Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69(12):2145–52.CrossRef
23.
go back to reference Burke-Miller JK, Weber K, Cohn SE, Hershow RC, Sha BE, French AL, et al. Neighborhood community characteristics associated with HIV disease outcomes in a cohort of urban women living with HIV. AIDS Care. 2016;28(10):1274–9.CrossRef Burke-Miller JK, Weber K, Cohn SE, Hershow RC, Sha BE, French AL, et al. Neighborhood community characteristics associated with HIV disease outcomes in a cohort of urban women living with HIV. AIDS Care. 2016;28(10):1274–9.CrossRef
24.
go back to reference Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, et al. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26(3):345–53.CrossRef Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, et al. Use of the community viral load as a population-based biomarker of HIV burden. AIDS. 2012;26(3):345–53.CrossRef
25.
go back to reference Shacham E, Lian M, Onen NF, Donovan M, Overton ET. Are neighborhood conditions associated with HIV management? HIV Med. 2013;14(10):624–32.CrossRef Shacham E, Lian M, Onen NF, Donovan M, Overton ET. Are neighborhood conditions associated with HIV management? HIV Med. 2013;14(10):624–32.CrossRef
26.
go back to reference Hatzakis GE, Mathur M, Gilbert L, Panos G, Wanchu A, Patel AK, et al. Neural network-longitudinal assessment of the Electronic Anti-Retroviral THerapy (EARTH) cohort to follow response to HIV-treatment. In AMIA Annu Symp Proc. 2005;301–305. Hatzakis GE, Mathur M, Gilbert L, Panos G, Wanchu A, Patel AK, et al. Neural network-longitudinal assessment of the Electronic Anti-Retroviral THerapy (EARTH) cohort to follow response to HIV-treatment. In AMIA Annu Symp Proc. 2005;301–305.
27.
go back to reference Kamal S, Urata J, Cavassini M, Liu H, Kouyos R, Bugnon O, et al. Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence. AIDS Care. 2021;33(4):530–6.CrossRef Kamal S, Urata J, Cavassini M, Liu H, Kouyos R, Bugnon O, et al. Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence. AIDS Care. 2021;33(4):530–6.CrossRef
28.
go back to reference Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.CrossRef Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.CrossRef
29.
go back to reference Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. hiv viral suppression trends over time among hiv-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376–84.CrossRef Nance RM, Delaney JAC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. hiv viral suppression trends over time among hiv-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376–84.CrossRef
30.
go back to reference Olatosi B, Weissman S, Zhang J, Chen S, Haider MR, Li X. Neighborhood matters: impact on time living with detectable viral load for new adult HIV diagnoses in South Carolina. AIDS Behav. 2020;24(4):1266–74.CrossRef Olatosi B, Weissman S, Zhang J, Chen S, Haider MR, Li X. Neighborhood matters: impact on time living with detectable viral load for new adult HIV diagnoses in South Carolina. AIDS Behav. 2020;24(4):1266–74.CrossRef
31.
go back to reference Xueying Yang JZ, Shujie C, Sharon W, Bankole O, Xiaoming L. Utilizing electronic health record data to understand comorbidity burden among people living with HIV: a machine learning approach. AIDS. 2020;Unpublished. Xueying Yang JZ, Shujie C, Sharon W, Bankole O, Xiaoming L. Utilizing electronic health record data to understand comorbidity burden among people living with HIV: a machine learning approach. AIDS. 2020;Unpublished.
32.
go back to reference Chen S. Association of longitudinal patterns of CD4, viral load and Non-AIDS Related Cancer. Big Data Conference 2020, Electronic Health Records Core. 2020. Chen S. Association of longitudinal patterns of CD4, viral load and Non-AIDS Related Cancer. Big Data Conference 2020, Electronic Health Records Core. 2020.
33.
go back to reference Olatosi B, Zhang J, Weissman S, Hu J, Haider MR, Li X. Using big data analytics to improve HIV medical care utilisation in South Carolina: a study protocol. BMJ Open. 2019;9(7):e027688.CrossRef Olatosi B, Zhang J, Weissman S, Hu J, Haider MR, Li X. Using big data analytics to improve HIV medical care utilisation in South Carolina: a study protocol. BMJ Open. 2019;9(7):e027688.CrossRef
36.
go back to reference SC DHEC. An Epidemiologic Profile of HIV and AIDS in South Carolina 2018. In: Division of Surveillance and Technical Support Bureau of Disease Control, editor. 2019. SC DHEC. An Epidemiologic Profile of HIV and AIDS in South Carolina 2018. In: Division of Surveillance and Technical Support Bureau of Disease Control, editor. 2019.
37.
go back to reference Olatosi BA, Probst JC, Stoskopf CH, Martin AB, Duffus WA. Patterns of engagement in care by HIV-infected adults: South Carolina, 2004–2006. AIDS. 2009;23(6):725–30.CrossRef Olatosi BA, Probst JC, Stoskopf CH, Martin AB, Duffus WA. Patterns of engagement in care by HIV-infected adults: South Carolina, 2004–2006. AIDS. 2009;23(6):725–30.CrossRef
38.
go back to reference Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection–South Carolina, 1997–2005. MMWR Morb Mortal Wkly Rep. 2006;55(47):1269–72. Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection–South Carolina, 1997–2005. MMWR Morb Mortal Wkly Rep. 2006;55(47):1269–72.
39.
go back to reference Truxillo C LB, Patetta M, et al. Advanced Business Analytics: SAS Institute Cary, NC, 2012. 2012. Truxillo C LB, Patetta M, et al. Advanced Business Analytics: SAS Institute Cary, NC, 2012. 2012.
41.
go back to reference Baldessarini RJ. Reducing suicide risk in psychiatric disorders. Curr Psychiatry. 2003;2(9):14–24. Baldessarini RJ. Reducing suicide risk in psychiatric disorders. Curr Psychiatry. 2003;2(9):14–24.
42.
go back to reference Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52(12):1458–65.CrossRef Kesselring A, Gras L, Smit C, van Twillert G, Verbon A, de Wolf F, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52(12):1458–65.CrossRef
43.
go back to reference Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23(13):1743.CrossRef Marin B, Thiébaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23(13):1743.CrossRef
44.
go back to reference Johnson AS, Johnson SD, Hu S, Li J, Yu C, Wu B, et al. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2017. 2019. Johnson AS, Johnson SD, Hu S, Li J, Yu C, Wu B, et al. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas, 2017. 2019.
45.
go back to reference Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019;6(2):e93–104.CrossRef Althoff KN, Gebo KA, Moore RD, Boyd CM, Justice AC, Wong C, et al. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. Lancet HIV. 2019;6(2):e93–104.CrossRef
46.
go back to reference Althoff KN, Gange S, Achenbach C. Smoking outweighs HIV-related risk factors for non-AIDS-defining cancers. Breast. 2015;42:7. Althoff KN, Gange S, Achenbach C. Smoking outweighs HIV-related risk factors for non-AIDS-defining cancers. Breast. 2015;42:7.
47.
go back to reference Yen IH, Kaplan GA. Neighborhood social environment and risk of death: multilevel evidence from the Alameda County Study. Am J Epidemiol. 1999;149(10):898–907.CrossRef Yen IH, Kaplan GA. Neighborhood social environment and risk of death: multilevel evidence from the Alameda County Study. Am J Epidemiol. 1999;149(10):898–907.CrossRef
48.
go back to reference Nagasako E, Waterman B, Reidhead M, Lian M, Gehlert S. Measuring subcounty differences in population health using hospital and census-derived data sets: the Missouri ZIP health rankings project. J Public Health Manage Pract. 2017;24:340–9.CrossRef Nagasako E, Waterman B, Reidhead M, Lian M, Gehlert S. Measuring subcounty differences in population health using hospital and census-derived data sets: the Missouri ZIP health rankings project. J Public Health Manage Pract. 2017;24:340–9.CrossRef
49.
go back to reference U.S. Department of Health Human S. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Washington, DC: DHHS. 2020. U.S. Department of Health Human S. Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Washington, DC: DHHS. 2020.
50.
go back to reference Shen Y, Liu T, Chen J, Li X, Liu L, Shen J, et al. Harnessing artificial intelligence to optimize long-term maintenance dosing for antiretroviral-naive adults with HIV-1 infection. Adv Therapeut. 2019;3(4):1900114.CrossRef Shen Y, Liu T, Chen J, Li X, Liu L, Shen J, et al. Harnessing artificial intelligence to optimize long-term maintenance dosing for antiretroviral-naive adults with HIV-1 infection. Adv Therapeut. 2019;3(4):1900114.CrossRef
51.
go back to reference Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, et al. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med. 2009;47(1):63–74.CrossRef Wang D, Larder B, Revell A, Montaner J, Harrigan R, De Wolf F, et al. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Artif Intell Med. 2009;47(1):63–74.CrossRef
52.
go back to reference Benitez AE, Musinguzi N, Bangsberg DR, Bwana MB, Muzoora C, Hunt PW, et al. Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda. J Int AIDS Soc. 2020;23(3):e25467.CrossRef Benitez AE, Musinguzi N, Bangsberg DR, Bwana MB, Muzoora C, Hunt PW, et al. Super learner analysis of real-time electronically monitored adherence to antiretroviral therapy under constrained optimization and comparison to non-differentiated care approaches for persons living with HIV in rural Uganda. J Int AIDS Soc. 2020;23(3):e25467.CrossRef
53.
go back to reference Ekpenyong ME, Etebong PI, Jackson TC. Fuzzy-multidimensional deep learning for efficient prediction of patient response to antiretroviral therapy. Heliyon. 2019;5(7):e02080.CrossRef Ekpenyong ME, Etebong PI, Jackson TC. Fuzzy-multidimensional deep learning for efficient prediction of patient response to antiretroviral therapy. Heliyon. 2019;5(7):e02080.CrossRef
54.
go back to reference Srivastava N, Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to prevent neural networks from overfitting. J Mach Learn Res. 2014;15(1):1929–58. Srivastava N, Hinton G, Krizhevsky A, Sutskever I, Salakhutdinov R. Dropout: a simple way to prevent neural networks from overfitting. J Mach Learn Res. 2014;15(1):1929–58.
Metadata
Title
Studying patterns and predictors of HIV viral suppression using A Big Data approach: a research protocol
Authors
Jiajia Zhang
Bankole Olatosi
Xueying Yang
Sharon Weissman
Zhenlong Li
Jianjun Hu
Xiaoming Li
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07047-5

Other articles of this Issue 1/2022

BMC Infectious Diseases 1/2022 Go to the issue